ANDA 202178, held by Watson Labs Inc. Colesevelam Hydrochloride.
As of Nov 15, 2026, ANDA 202178 (Colesevelam Hydrochloride), held by Watson Labs Inc, was first approved by FDA on Sep 1, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 1, 2020 | Original application | Approved | None posted |
| Colesevelam Hydrochloride1.875GM/PACKET · for suspension;oral | Colesevelam Hydrochloride | Discontinued |
| Colesevelam Hydrochloride3.75GM/PACKET · for suspension;oral | Colesevelam Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters